LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarkers Help Diagnose Mild Cognitive Impairment in Diabetics

By LabMedica International staff writers
Posted on 02 Mar 2016
Image: Dot blots showing the expressions of total glycogen synthase kinase-3β (tGSK-3β) and p-GSK-3β (ser9) in the platelets; the differences of platelet GSK-3β activity between T2DM-nMCI group and T2DM-MCI group (Photo courtesy of Tongji Medical College).
Image: Dot blots showing the expressions of total glycogen synthase kinase-3β (tGSK-3β) and p-GSK-3β (ser9) in the platelets; the differences of platelet GSK-3β activity between T2DM-nMCI group and T2DM-MCI group (Photo courtesy of Tongji Medical College).
Alzheimer's disease is the most common cause of senile dementia, and the prevalence is increasing with population aging and even when the clinical diagnosis of Alzheimer's disease is made, it is generally too late to be curable.

Type 2 diabetes mellitus (T2DM) is also an age-associated disorder, and the patients with T2DM show a significantly increased risk to suffer from Alzheimer's disease. Biomarkers that can diagnose or predict conversion of T2DM into Alzheimer's disease would make it possible to start an early intervention, and eventually reduces the incidence of Alzheimer's disease.

Scientists at the Huazhong University of Science and Technology (Wuhan, China) and their colleagues recruited 646 T2DM patients from January 2012 to May 2015 from five hospitals. Patients in each set were randomly divided into two groups: T2DM without mild cognitive impairment (MCI) (termed T2DM-nMCI) or with MCI (termed T2DM-MCI). Glycogen synthase kinase-3β (GSK-3β) activity in platelets, ApoE genotypes in leucocytes and the olfactory function were detected by Western/dot blotting.

For biochemical indicators, all participants were asked to measure fasting blood glucose, postprandial blood glucose, serum insulin, hemoglobinA1c (HbA1c) and serum magnesium, the next morning. On receipt, serum, leukocytes and platelet samples were separated from EDTA whole blood by centrifugation, which were collected and stored at -80 °C until analysis. The total GSK-3β (tGSK-3β) and serine-9 phosphorylated GSK-3β (pS9GSK-3β, the inactive form of the kinase) in serum or platelet were measured by ELISA (Cusabio Biotech Co., Ltd.; Wuhan, China), Western blotting or dot blotting. In addition, the biochemical activity of GSK-3β in platelet was measured by using enzyme activity assay kit.

The scientists found no significant differences for sex, T2DM years, hypertension, hyperlipidemia, coronary disease, complications, insulin treatment, HbA1c, ApoE ε2, ApoE ε3, tGSK3β and pS9GSK3β between the two groups. They did find that that activation of the peripheral circulating GSK-3β, expression of ApoE ε4, dysfunction of the olfactory function, and aging are diagnostic for the mild cognitive impairment in T2DM patients, and combination of these factors can significantly improve the diagnostic accuracy. They also developed a simple protocol for measuring the total and the inactivated form of GSK-3β in human platelets. As the method is simple and easy to operate with low cost and good repeatability, it is suitable for application in clinical laboratories.

Jian-Zhi Wang, PhD, a professor and senior author of the study, said, “Although we have designed training set and validation set respectively to assure the correlation of cognitive impairments with the biomarkers, further longitudinal studies are needed to confirm how informative these biomarkers in predicting the conversion of T2DM into Alzheimer's disease.” The study was published on February 13, 2016, in the journal EbioMedicine.

Related Links:

Huazhong University of Science and Technology
Cusabio Biotech 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.

Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more